Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on November 1, 2012. The filing serves to announce the company's financial results for the fiscal quarter ended September 30, 2012.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached earnings press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the quarter ended September 30, 2012, by reviewing Exhibit 99.1 (Earnings Press Release).
- Confirm the company's cash position and liquidity status as detailed in the full press release.
- Review the full text of the press release for any updated financial guidance or operational outlook not present in this summary filing.
- Note that the financial data in this 8-K is furnished for informational purposes and is not incorporated by reference into other SEC filings unless explicitly stated.